MedicalResearch.com Interview with:
Dorota Drozdz M.D., Ph.D
Response: In Poland and Portugal we use EPO beta for anemia treatment. Our interest was to find differences in clinical patterns taking in consideration that both countries are adherent to KDIGO recommendations an guidelines.
We found that in both countries the mean hemoglobin (Hb) level and percentage of patients in target Hb level (10-12 g/dl on ESA treatment) are the same, but the approaches were different – in Poland the ESA dose was statistically lower than in Portugal and iron dose was statistically higher than in Portugal. Most other lab tests results were similar. Future secondary outcomes analysis should answer the question, which method is safer.
MedicalResearch.com: What should readers take away from your report?
Response: Even being adherent to the same recommendations or guidelines there are different ways to achieve the goal – full analysis should answer which method is safer.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: Presented poster contains the interim analysis of the study. At the end of the year we will have the complete data including secondary outcomes like hospitalization
and mortality – full analysis is planned to be presented on EDTA Madrid Congress,
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Achievement of Renal Anemia KDIGO Targets by Two Different Strategies – A European Hemodialysis Multicenter Analysis
Drozdz M, MD, PhD;1 Jacobson SH, MD, PhD; 2,3 Kleophas W, MD; 4 Krishnan M, MD; 5 Alsuwaida A, MD; 6 Silva F, RN; 7 and Weigert A, MD7 1 DaVita, Poland, 2 Karolinska Institutet, Stockholm, Sweden, 3 DaVita EMEA, 4 DaVita Germany, 5 DaVita US, 6 DaVita Saudi Arabia, 7 Davita Portugal
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.
More Medical Research Interviews on MedicalResearch.com